CP-25 exerts anti-angiogenic effects on a rat model of adjuvant-induced arthritis by promoting GRK2-induced downregulation of CXCR4-ERK1/2 signaling in endothelial cells

Zhang,Min; Gao,Mei; Chen,Jinyu; Song,Lihua; Wei,Wei

doi:10.3892/mmr.2019.10765

CP-25 exerts anti-angiogenic effects on a rat model of adjuvant-induced arthritis by promoting GRK2-induced downregulation of CXCR4-ERK1/2 signaling in endothelial cells

Authors:
- Min Zhang
- Mei Gao
- Jinyu Chen
- Lihua Song
- Wei Wei
View Affiliations

Affiliations: Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Hefei, Anhui 230032, P.R. China
Published online on: October 23, 2019 https://doi.org/10.3892/mmr.2019.10765
Pages: 4831-4842
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis can produce an invasive and destructive front, also named a pannus, comprised of inflammatory vascular tissue that covers and erodes articular cartilage, subchondral bone and peri‑articular soft tissues in rheumatoid arthritis (RA). Paeoniflorin‑6'‑O‑benzene sulfonate (CP‑25) is a novel ester derivative of paeoniflorin. We previously demonstrated that CP‑25 exerts anti‑inflammatory and immunoregulatory effects. CP‑25 also exhibits a marked therapeutic effect on adjuvant‑induced arthritis (AA), and is able to inhibit synovial and immune cell function, according to our previous study. However, the effect of CP‑25 on angiogenesis remains unclear. In the present study, AA was initiated in Sprague‑Dawley rats via intradermal immunization in the right hind metatarsal footpad with heat‑killed Mycobacterium butyricum in liquid paraffin, and rats were divided into four groups: Normal, AA rat model, CP‑25 (50 mg/kg) and methotrexate (0.5 mg/kg) groups (n=10 rats/group). Subsequently, joint synovium in AA rats was pathologically evaluated by hematoxylin and eosin staining, synovial vascular proliferation was evaluated by immunofluorescence, the synovial expression levels of C‑X‑C motif chemokine ligand 12 (CXCL12) were detected by immunohistochemistry and ELISA, and synovial C‑X‑C chemokine receptor type 4 (CXCR4) was detected by western blotting. The results demonstrated that CP‑25 ameliorated clinical signs and pannus formation in the ankle joint in rats with AA. Furthermore, there was a positive correlation between pannus score and CXCL12 and CXCR4 expression. In addition, the effects of CP‑25 on endothelial cell function and CXCL12/CXCR4 signaling were studied in vitro using human umbilical vein endothelial cells (HUVECs). The results demonstrated that CXCL12 significantly promoted HUVEC proliferation, migration and tube formation, and that CP‑25 could reverse these abnormalities by inhibiting plasma membrane localization of G protein‑coupled receptor kinase 2 (GRK2) in HUVECs. These findings suggested that CP‑25 may markedly inhibit pannus formation in AA. This effect may be associated with a reduction in the plasma membrane localization of GRK2 in endothelial cells, an enhancement of the inhibitory effect of GRK2 on ERK1/2 in the cytoplasm, a reduction in the phosphorylation of ERK1/2 and in the function of HUVECs.

View Figures

View References

1	Bottini N and Firestein GS: Duality of fibroblast-like synoviocytes in RA: Passive responders and imprinted aggressors. Nat Rev Rheumatol. 9:24–33. 2013. View Article : Google Scholar : PubMed/NCBI
2	McInnes IB and Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med. 365:2205–2219. 2011. View Article : Google Scholar : PubMed/NCBI
3	Choudhary N, Bhatt LK and Prabhavalkar KS: Experimental animal models for rheumatoid arthritis. Immunopharmacol Immunotoxicol. 40:193–200. 2018. View Article : Google Scholar : PubMed/NCBI
4	Elshabrawy HA, Chen Z, Volin MV, Ravella S, Virupannavar S and Shahrara S: The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis. 18:433–448. 2015. View Article : Google Scholar : PubMed/NCBI
5	Szekanecz Z and Koch AE: Vascular involvement in rheumatic diseases: ‘Vascular rheumatology’. Arthritis Res Ther. 10:2242008. View Article : Google Scholar : PubMed/NCBI
6	Lainer-Carr D and Brahn E: Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol. 3:434–442. 2007. View Article : Google Scholar : PubMed/NCBI
7	Komatsu N and Takayanagi H: Bone and cartilage destruction in rheumatoid arthritis. Clin Calcium. 22:179–185. 2012.(In Japanese). PubMed/NCBI
8	Kawaguchi N, Zhang TT and Nakanishi T: Involvement of CXCR4 in normal and abnormal development. Cells. 8:E1852019. View Article : Google Scholar : PubMed/NCBI
9	Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL and Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121:335–348. 2005. View Article : Google Scholar : PubMed/NCBI
10	Patrussi L and Baldari CT: The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection. Curr Med Chem. 18:497–512. 2011. View Article : Google Scholar : PubMed/NCBI
11	Pablos JL, Santiago B, Galindo M, Torres C, Brehmer MT, Blanco FJ and García-Lázaro FJ: Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol. 170:2147–2152. 2003. View Article : Google Scholar : PubMed/NCBI
12	Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, et al: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 393:591–594. 1998. View Article : Google Scholar : PubMed/NCBI
13	Blades MC, Ingegnoli F, Wheller SK, Manzo A, Wahid S, Panayi GS, Perretti M and Pitzalis C: Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice. Arthritis Rheum. 46:824–836. 2002. View Article : Google Scholar : PubMed/NCBI
14	Kanbe K, Chiba J, Inoue Y, Taguchi M and Yabuki A: SDF-1 and CXCR4 in synovium are associated with disease activity and bone and joint destruction in patients with rheumatoid arthritis treated with golimumab. Mod Rheumatol. 26:46–50. 2016. View Article : Google Scholar : PubMed/NCBI
15	Zhang F, Shu JL, Li Y, Wu YJ, Zhang XZ, Han L, Tang XY, Wang C, Wang QT, Chen JY, et al: CP-25, a novel anti-inflammatory and immunomodulatory drug, inhibits the functions of activated human B cells through regulating BAFF and TNF-α signaling and comparative efficacy with biological agents. Front Pharmacol. 8:9332017. View Article : Google Scholar : PubMed/NCBI
16	Jia XY, Chang Y, Sun XJ, Wu HX, Wang C, Xu HM, Zhang L, Zhang LL, Zheng YQ, Song LH, et al: Total glucosides of paeony inhibit the proliferation of fibroblast-like synoviocytes through the regulation of G proteins in rats with collagen-induced arthritis. Int Immunopharmacol. 18:1–6. 2014. View Article : Google Scholar : PubMed/NCBI
17	Wu H, Wei W, Song L, Zhang L, Chen Y and Hu X: Paeoniflorin induced immune tolerance of mesenteric lymph node lymphocytes via enhancing beta 2-adrenergic receptor desensitization in rats with adjuvant arthritis. Int Immunopharmacol. 7:662–673. 2007. View Article : Google Scholar : PubMed/NCBI
18	Wang QT, Zhang LL, Wu HX and Wei W: The expression change of β-arrestins in fibroblast-like synoviocytes from rats with collagen-induced arthritis and the effect of total glucosides of paeony. J Ethnopharmacol. 133:511–516. 2011. View Article : Google Scholar : PubMed/NCBI
19	Wang C, Yuan J, Wu HX, Chang Y, Wang QT, Wu YJ, Liu LH and Wei W: Paeoniflorin inhibits inflammatory responses in mice with allergic contact dermatitis by regulating the balance between inflammatory and anti-inflammatory cytokines. Inflamm Res. 62:1035–1044. 2013. View Article : Google Scholar : PubMed/NCBI
20	Zhang LL, Wei W, Wang NP, Wang QT, Chen JY, Chen Y, Wu H and Hu XY: Paeoniflorin suppresses inflammatory mediator production and regulates G protein-coupled signaling in fibroblast-like synoviocytes of collagen induced arthritic rats. Inflamm Res. 57:388–395. 2008. View Article : Google Scholar : PubMed/NCBI
21	Chen JY, Wu HX, Chen Y, Zhang LL, Wang QT, Sun WY and Wei W: Paeoniflorin inhibits proliferation of fibroblast-like synoviocytes through suppressing G-protein-coupled receptor kinase 2. Planta Med. 78:665–671. 2012. View Article : Google Scholar : PubMed/NCBI
22	Chang Y, Zhang L, Wang C, Jia XY and Wei W: Paeoniflorin inhibits function of synoviocytes pretreated by rIL-1α and regulates EP4 receptor expression. J Ethnopharmacol. 137:1275–1282. 2011. View Article : Google Scholar : PubMed/NCBI
23	Chang Y, Wei W, Zhang L and Xu HM: Effects and mechanisms of total glucosides of paeony on synoviocytes activities in rat collagen-induced arthritis. J Ethnopharmacol. 121:43–48. 2009. View Article : Google Scholar : PubMed/NCBI
24	Liu ZQ, Jiang ZH, Liu L and Hu M: Mechanisms responsible for poor oral bioavailability of paeoniflorin: Role of intestinal disposition and interactions with sinomenine. Pharm Res. 23:2768–2780. 2006. View Article : Google Scholar : PubMed/NCBI
25	Wang C, Yuan J, Yang ZY, Nie XX, Song LH and Wei W: Pharmacokinetics of paeoniflorin microemulsion after repeated dosing in rats with adjuvant arthritis. Pharmazie. 67:997–1001. 2012.PubMed/NCBI
26	Wang C, Yuan J, Zhang LL and Wei W: Pharmacokinetic comparisons of Paeoniflorin and Paeoniflorin-6′O-benzene sulfonate in rats via different routes of administration. Xenobiotica. 46:1142–1150. 2016. View Article : Google Scholar : PubMed/NCBI
27	Yang XD, Wang C, Zhou P, Yu J, Asenso J, Ma Y and Wei W: Absorption characteristic of paeoniflorin-6-O-benzene sulfonate (CP-25) in in situ single-pass intestinal perfusion in rats. Xenobiotica. 46:775–783. 2016. View Article : Google Scholar : PubMed/NCBI
28	Chang Y, Jia X, Wei F, Wang C, Sun X, Xu S, Yang X, Zhao Y, Chen J, Wu H, et al: CP-25, a novel compound, protects against autoimmune arthritis by modulating immune mediators of inflammation and bone damage. Sci Rep. 6:262392016. View Article : Google Scholar : PubMed/NCBI
29	Jia X, Wei F, Sun X, Chang Y, Xu S, Yang X, Wang C and Wei W: CP-25 attenuates the inflammatory response of fibroblast-like synoviocytes co-cultured with BAFF-activated CD4(+) T cells. J Ethnopharmacol. 189:194–201. 2016. View Article : Google Scholar : PubMed/NCBI
30	Sun WY, Wu JJ, Peng WT, Sun JC and Wei W: The role of G protein-coupled receptor kinases in the pathology of malignant tumors. Acta Pharmacol Sin. 39:1699–1705. 2018. View Article : Google Scholar : PubMed/NCBI
31	Premont RT and Gainetdinov RR: Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol. 69:511–534. 2007. View Article : Google Scholar : PubMed/NCBI
32	Métayé T, Gibelin H, Perdrisot R and Kraimps JL: Pathophysiological roles of G-protein-coupled receptor kinases. Cell Signal. 17:917–928. 2005. View Article : Google Scholar : PubMed/NCBI
33	Yu H, Yang YH, Rajaiah R and Moudgil KD: Nicotine-induced differential modulation of autoimmune arthritis in the Lewis rat involves changes in interleukin-17 and anti-cyclic citrullinated peptide antibodies. Arthritis Rheum. 63:981–991. 2011. View Article : Google Scholar : PubMed/NCBI
34	Chen J, Wang Q, Wu H, Liu K, Wu Y, Chang Y and Wei W: The ginsenoside metabolite compound K exerts its anti-inflammatory activity by downregulating memory B cell in adjuvant-induced arthritis. Pharm Biol. 54:1280–1288. 2016. View Article : Google Scholar : PubMed/NCBI
35	Wang Y, Han CC, Cui D, Luo TT, Li Y, Zhang Y, Ma Y and Wei W: Immunomodulatory Effects of CP-25 on splenic T cells of rats with adjuvant arthritis. Inflammation. 41:1049–1063. 2018. View Article : Google Scholar : PubMed/NCBI
36	Semerano L, Clavel G, Assier E, Denys A and Boissier MC: Blood vessels, a potential therapeutic target in rheumatoid arthritis? Joint Bone Spine. 78:118–123. 2011. View Article : Google Scholar : PubMed/NCBI
37	Khan A, Greenman J and Archibald SJ: Small molecule CXCR4 chemokine receptor antagonists: Developing drug candidates. Curr Med Chem. 14:2257–2277. 2007. View Article : Google Scholar : PubMed/NCBI
38	Hatse S, Princen K, Bridger G, De Clercq E and Schols D: Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527:255–262. 2002. View Article : Google Scholar : PubMed/NCBI
39	Matsuo Y, Ochi N, Sawai H, Yasuda A, Takahashi H, Funahashi H, Takeyama H, Tong Z and Guha S: CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer. 124:853–861. 2009. View Article : Google Scholar : PubMed/NCBI
40	Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, Kleinman HK, Murphy WJ and Oppenheim JJ: Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol. 154:1125–1135. 1999. View Article : Google Scholar : PubMed/NCBI
41	Gurevich EV, Tesmer JJ, Mushegian A and Gurevich VV: G protein-coupled receptor kinases: More than just kinases and not only for GPCRs. Pharmacol Ther. 133:40–69. 2012. View Article : Google Scholar : PubMed/NCBI
42	Brondello JM, Pouysségur J and McKenzie FR: Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science. 286:2514–2517. 1999. View Article : Google Scholar : PubMed/NCBI
43	Wang Q, Wang L, Wu L, Zhang M, Hu S, Wang R, Han Y, Wu Y, Zhang L, Wang X, et al: Paroxetine alleviates T lymphocyte activation and infiltration to joints of collagen-induced arthritis. Sci Rep. 7:453642017. View Article : Google Scholar : PubMed/NCBI
44	Penela P, Ruiz-Gómez A, Castaño JG and Mayor F Jr: Degradation of the G protein-coupled receptor kinase 2 by the proteasome pathway. J Biol Chem. 273:35238–35244. 1998. View Article : Google Scholar : PubMed/NCBI
45	Woodard LE and Nimmagadda S: CXCR4-based imaging agents. J Nucl Med. 52:1665–1669. 2011. View Article : Google Scholar : PubMed/NCBI
46	Clift IC, Bamidele AO, Rodriguez-Ramirez C, Kremer KN and Hedin KE: β-Arrestin1 and distinct CXCR4 structures are required for stromal derived factor-1 to downregulate CXCR4 cell-surface levels in neuroblastoma. Mol Pharmacol. 85:542–552. 2014. View Article : Google Scholar : PubMed/NCBI
47	Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M and Benovic JL: Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem. 285:7805–7817. 2010. View Article : Google Scholar : PubMed/NCBI
48	Cheng ZJ, Zhao J, Sun Y, Hu W, Wu YL, Cen B, Wu GX and Pei G: β-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between β-arrestin and CXCR4. J Biol Chem. 275:2479–2485. 2000. View Article : Google Scholar : PubMed/NCBI